Ani Pharmaceuticals Stock Today
| ANIP Stock | USD 72.95 2.26 3.20% |
PerformanceGood
| Odds Of DistressLow
|
ANI Pharmaceuticals is selling at 72.95 as of the 3rd of May 2025; that is 3.20 percent increase since the beginning of the trading day. The stock's last reported lowest price was 70.06. ANI Pharmaceuticals has about a 24 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 14th of May 2023 and ending today, the 3rd of May 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of May 2000 | Category Healthcare | Classification Health Care |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota. The company has 21.57 M outstanding shares of which 2.36 M shares are presently shorted by private and institutional investors with about 5.71 trading days to cover. More on ANI Pharmaceuticals
Moving against ANI Stock
ANI Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Nikhil Lalwani | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsANI Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ANI Pharmaceuticals' financial leverage. It provides some insight into what part of ANI Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ANI Pharmaceuticals (ANIP) is traded on NASDAQ Exchange in USA. It is located in 210 Main Street West, Baudette, MN, United States, 56623 and employs 897 people. ANI Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.53 B. ANI Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 21.57 M outstanding shares of which 2.36 M shares are presently shorted by private and institutional investors with about 5.71 trading days to cover.
ANI Pharmaceuticals currently holds about 63.38 M in cash with 64.02 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.89.
Check ANI Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationANI Pharmaceuticals holds a total of 21.57 Million outstanding shares. The majority of ANI Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ANI Pharmaceuticals to benefit from reduced commissions. Thus, institutional investors are subject to a different set of regulations than regular investors in ANI Pharmaceuticals. Please pay attention to any change in the institutional holdings of ANI Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that nearly one million six hundred two thousand nine hundred sixty-three invesors are currently shorting ANI Pharmaceuticals expressing very little confidence in its future performance.
Check ANI Ownership Details
ANI Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Macquarie Group Ltd | 2024-12-31 | 562.6 K | |
| William Blair Investment Management, Llc | 2024-12-31 | 485.3 K | |
| Geode Capital Management, Llc | 2024-12-31 | 429 K | |
| Tang Capital Management Llc | 2024-12-31 | 317.5 K | |
| Thompson, Siegel & Walmsley Llc | 2024-12-31 | 283.9 K | |
| Ameriprise Financial Inc | 2024-12-31 | 271.8 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 268.1 K | |
| Aberdeen Group Plc | 2024-12-31 | 238 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 236.2 K | |
| Blackrock Inc | 2024-12-31 | 2.7 M | |
| Vanguard Group Inc | 2024-12-31 | 1.3 M |
ANI Pharmaceuticals Historical Income Statement
ANI Stock Against Markets
ANI Pharmaceuticals Corporate Management
| Meredith Cook | General VP | Profile | |
| Elizabeth JD | Chief Disease | Profile | |
| Krista Davis | Senior Officer | Profile | |
| Muthusamy RPh | COO RD | Profile | |
| Thomas Rowland | Senior Brands | Profile |
Already Invested in ANI Pharmaceuticals?
The danger of trading ANI Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ANI Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ANI Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ANI Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.